Core Points - The company and its subsidiaries provided a total guarantee of 231.46 million yuan to meet operational and business development needs, while releasing guarantees totaling 337.60 million yuan in September 2025 [2][4] - The board of directors approved a total guarantee limit of up to 7 billion yuan for the year 2025, allowing for inter-company guarantees within the approved limit [4][7] - As of the announcement date, the total external guarantees provided by the company and its subsidiaries amounted to 2.47 billion yuan, representing 32.40% of the latest audited net assets [8] Guarantee Details - The guarantees provided are classified as routine guarantees, with specific amounts detailed for each subsidiary [4][5] - The guarantees are primarily aimed at satisfying the funding needs for production and business development, aligning with the company's overall interests and strategic goals [6][7] - The company maintains absolute control over the operations and financial conditions of the guaranteed subsidiaries, ensuring manageable risk levels [6][7] Board's Opinion - The board believes that providing guarantees to subsidiaries is a reasonable prediction based on business development needs and financing requirements, which will benefit the company's main operations and enhance future economic benefits [7] - The financial stability and creditworthiness of the guaranteed entities are affirmed, with the company capable of effectively controlling financial risks [7] Guarantee Agreement - The guarantees are structured as joint liability guarantees with a term of three years from the debt performance deadline [10] - The total guarantee amount is 231.46 million yuan, reflecting the company's commitment to supporting its subsidiaries [10]

| 证券代码：603368 | 证券简称：柳药集团 公告编号：2025-087 | | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | 广西柳药集团股份有限公司 关于公司及下属控股子公司提供担保的进展公告 担保对象及基本情况 | | 被担保人名称 | 万元 | | 广西柳药集团股份有限公司（简称"公司"） | | --- | --- | --- | --- | --- | | | 本次担保金额 | 11,621.83 | | | | 担保 对象一 | 实际为其提供的担保余额 | 27,152.66 | | 万元（含本次） | | | 是否在前期预计额度内 | 是 | □否 | 不适用：_________ | | | 本次担保是否有反担保 | □是 | 否 | 不适用：_________ | | 担保 | 被担保人名称 | | | 广西南宁柳药药业有限公司（简称"南宁柳药"） | | | 本次担保金额 | 6,524.61 | 万元 | | | 对象二 | 实际为其提供的担保余额 | 124,874.45 | | 万元（含本次） | | | 是否在前期预计额度内 | 是 | ...

Core Viewpoint - The company is focusing on transforming its business model from "pharmaceutical sales" to "health services" by implementing chronic disease management projects targeted at middle-aged and elderly populations, utilizing AI consultation and digital health services [1] Group 1: Business Strategy - The company aims to create a differentiated advantage through the implementation of chronic disease management projects and digital health services [1] - The strategy includes leveraging its self-operated internet hospital to provide online diagnosis, chronic disease prescription renewals, and health consultations [1] - The goal is to integrate online and offline medical services with retail pharmacy professional purchasing and health management services, establishing a comprehensive "new retail" ecosystem [1] Group 2: Financial Performance - In the first half of 2025, the company reported revenue of 10.301 billion yuan, a year-on-year decrease of 3.21% [1] - The net profit attributable to the parent company was 429 million yuan, reflecting a year-on-year decline of 7.52% [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 ● 会议召开方式：上证路演中心网络互动 ● 问题征集方式：投资者可于2025年10月13日（星期一）至10月17日(星期五)16:00前登录上证路演中心 网站首页点击"提问预征集"栏目或通过公司邮箱lygf@lzyy.cn进行提问。公司将在2025年半年度业绩说 明会（以下简称"本次业绩说明会"）上对投资者普遍关注的问题进行回答。 广西柳药集团股份有限公司（以下简称"公司"）已于2025年8月29日在上海证券交易所网站 （http://www.sse.com.cn）披露《2025年半年度报告》，为便于广大投资者更全面深入地了解公司2025 年半年度的经营成果、财务状况，公司决定于2025年10月20日（星期一）15:00-16:00召开本次业绩说明 会，就投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以网络互动形式召开，公司将针对2025年半年度经营成果及财务指标的具体情况与投资 者进行互动交流和沟通，在信息披露允许的范围内就投资者普遍关注的公司经营业绩、战略规划、财务 状况等问题进行回答，欢迎广大投资者积极参与。 二、说明会召开的时间、地点及方式 ...

Core Insights - The pharmaceutical commercial sector saw a slight increase of 0.17% on October 10, with Guofa Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Stock Performance - Guofa Co., Ltd. (600538) closed at 5.85, up 4.28% with a trading volume of 178,800 shares and a transaction value of 103 million yuan [1] - Other notable gainers included Dajia Weikang (301126) up 1.89%, Yingte Group (000411) up 1.77%, and Liuyao Group (603368) up 1.75% [1] - Conversely, the sector also experienced declines, with Saily Medical (603716) down 4.51% and Jianfa Zhixin (301584) down 4.01% [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 161 million yuan from institutional investors, while retail investors saw a net inflow of 214 million yuan [2] - The data indicates that while institutional investors were pulling back, retail investors were actively buying into the sector [2] Individual Stock Capital Flow - Shanghai Pharmaceuticals (601607) had a net inflow of 27.32 million yuan from institutional investors, while it faced a net outflow of 32.58 million yuan from speculative funds [3] - Dajia Weikang (301126) saw a net inflow of 4.95 million yuan from institutional investors, but also faced outflows from speculative funds [3] - Guofa Co., Ltd. (600538) had a net inflow of 4.07 million yuan from institutional investors, indicating some level of interest despite the overall outflow trend [3]

重要内容提示： ● 问题征集方式：投资者可于2025年10月13日（星期一）至10月17日(星期 五)16:00前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 lygf@lzyy.cn进行提问。公司将在2025年半年度业绩说明会（以下简称"本次业 绩说明会"）上对投资者普遍关注的问题进行回答。 | 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-086 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 重要内容提示： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 三、参加人员 广西柳药集团股份有限公司（以下简称"公司"）已于2025年8月29日在上海 证券交易所网站（http://www.sse.com.cn）披露《2025年半年度报告》，为便于广 大投资者更全面深入地了解公司2025年半年度的经营成果、财务状况，公司决定 于2025年10月20日（星期一 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301015 | 百洋医药 | 27.17 | -2.96% | 5.74万 | 1.58亿 | | 301584 | C建发致 | 28.15 | -2.90% | 21.71万 | 6.15亿 | | 600833 | 第一医药 | 13.38 | -2.76% | 8.11万 | 260'T | | 301126 | 达嘉维康 | 11.13 | -2.37% | 4.04万 | 4537.69万 | | 603108 | 润达医疗 | 15.70 | -1.88% | 19.17万 | 3.00亿 | | 000705 | 浙江震元 | 9.78 | -1.41% | 13.46万 | 1.31亿 | | 002462 | 章章点 | 13.69 | -0.58% | 4.41万 | 6013.33万 | | 300937 | 药易购 | 26.53 | -0.49% | 1.29万 | 3415.25万 | | 600538 | 国发股份 ...

格隆汇10月9日丨柳药集团(603368.SH)公布，截至2025年9月30日，公司通过集中竞价交易方式回购股 份数量为810.79万股，已回购股份占公司目前总股本的比例为2.04%，较上次回购进展公告披露数无变 化，回购成交的最高价为18.60元/股、最低价为17.83元/股，已支付的总金额为14,846.49万元（不含交 易费用）。 ...

格隆汇10月9日丨柳药集团(603368.SH)公布，截至2025年9月30日，公司通过集中竞价交易方式回购股 份数量为810.79万股，已回购股份占公司目前总股本的比例为2.04%，较上次回购进展公告披露数无变 化，回购成交的最高价为18.60元/股、最低价为17.83元/股，已支付的总金额为14,846.49万元（不含交 易费用）。 ...

重要内容提示： | 回购方案首次披露日 | 2025/7/26 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 7 月 7 | 25 | 日~2026 | 年 | 月 | 24 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 810.79万股 | | | | | | | 累计已回购股数占总股本比例 | 2.04% | | | | | | | 累计已回购金额 | 14,846.49万元 | | | | | | | 实际回购价格区间 | 17.83元/股~18.60元/股 | | | | | | 一、回购股份的基本情况 广西柳药集团股份有限公司（以下简称"公司"）于 2025 年 7 月 25 日召开第 五届董事会第二十七次会议，审议通过了《关于以 ...